Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract 2600: HMGB1, a potential new target for mesothelioma therapy

View through CrossRef
Abstract Malignant mesothelioma (MM) is a very aggressive cancer that causes 2000-3000 deaths annually in the U.S. and is resistant to current therapies. Diagnosis frequently occurs at a late stage of disease progression and median survival from time of diagnosis is about 1 year. Therefore, novel therapeutic strategies are urgently needed. We found previously that High-Mobility Group Box 1 protein (HMGB1), a known pro-inflammatory cytokine, induces tumor necrosis factor-alpha (TNF-α) secretion, potentiates survival of asbestos-exposed primary human mesothelial cells (HM) and enables HM malignant transformation, which leads to the initiation of MM. We show here that HMGB1 is also critical in the maintenance and progression of established MM. We found that HMGB1 is highly expressed in MM tissues and its levels in MM patients’ sera are significantly higher than in those of healthy individuals (P < 0.0001). MM tumor cells over-express HMGB1 in both the nucleus and cytoplasm. Instead, normal HM only express nuclear HMGB1 at significantly lower level than MM cells. The main receptor of HMGB1, receptor for advanced glycation end products (RAGE), is also upregulated in MM cells compared to HM. MM cells release biologically active HMGB1 into extra-cellular space, and the interaction with its receptors induces cell proliferation and chemo-attractant activity on MM cells. Moreover, the interference with HMGB1 activity by using specific HMGB1 inhibitors, such as BoxA and HMGB1 neutralizing monoclonal antibodies, leads to MM cell death. HMGB1 inhibitors impair MM cells migration, invasion, wound healing and also colony formation in soft agar. Our results strongly suggest that HMGB1 can be a novel target for mesothelioma therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2600. doi:10.1158/1538-7445.AM2011-2600
Title: Abstract 2600: HMGB1, a potential new target for mesothelioma therapy
Description:
Abstract Malignant mesothelioma (MM) is a very aggressive cancer that causes 2000-3000 deaths annually in the U.
S.
and is resistant to current therapies.
Diagnosis frequently occurs at a late stage of disease progression and median survival from time of diagnosis is about 1 year.
Therefore, novel therapeutic strategies are urgently needed.
We found previously that High-Mobility Group Box 1 protein (HMGB1), a known pro-inflammatory cytokine, induces tumor necrosis factor-alpha (TNF-α) secretion, potentiates survival of asbestos-exposed primary human mesothelial cells (HM) and enables HM malignant transformation, which leads to the initiation of MM.
We show here that HMGB1 is also critical in the maintenance and progression of established MM.
We found that HMGB1 is highly expressed in MM tissues and its levels in MM patients’ sera are significantly higher than in those of healthy individuals (P < 0.
0001).
MM tumor cells over-express HMGB1 in both the nucleus and cytoplasm.
Instead, normal HM only express nuclear HMGB1 at significantly lower level than MM cells.
The main receptor of HMGB1, receptor for advanced glycation end products (RAGE), is also upregulated in MM cells compared to HM.
MM cells release biologically active HMGB1 into extra-cellular space, and the interaction with its receptors induces cell proliferation and chemo-attractant activity on MM cells.
Moreover, the interference with HMGB1 activity by using specific HMGB1 inhibitors, such as BoxA and HMGB1 neutralizing monoclonal antibodies, leads to MM cell death.
HMGB1 inhibitors impair MM cells migration, invasion, wound healing and also colony formation in soft agar.
Our results strongly suggest that HMGB1 can be a novel target for mesothelioma therapy.
Citation Format: {Authors}.
{Abstract title} [abstract].
In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL.
Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2600.
doi:10.
1158/1538-7445.
AM2011-2600.

Related Results

ROLE OF HMGB1 IN DOXORUBICIN-INDUCED MYOCARDIAL APOPTOSIS AND ITS REGULATION PATHWAY
ROLE OF HMGB1 IN DOXORUBICIN-INDUCED MYOCARDIAL APOPTOSIS AND ITS REGULATION PATHWAY
Objectives Doxorubicin (DOX) is a widely used anti-tumour agent. The clinical application of the medication is limited by its side effect which can elicit myocard...
HMGB1 mediates lipopolysaccharide-induced macrophage autophagy and pyroptosis
HMGB1 mediates lipopolysaccharide-induced macrophage autophagy and pyroptosis
Abstract Autophagy and pyroptosis of macrophages play important protective or detrimental roles in sepsis. However, the underlying mechanisms remain unclear. High mobility ...
Role of HMGB1 in Cisplatin-Persistent Lung Adenocarcinoma Cell Lines
Role of HMGB1 in Cisplatin-Persistent Lung Adenocarcinoma Cell Lines
Significant advances have been made recently in the development of targeted therapy for lung adenocarcinoma. However, platinum-based chemotherapy remains as the cornerstone in the ...
Is anti-HMGB1 Antibody a Potential Characteristic Autoantibody for Sjögren's Syndrome?
Is anti-HMGB1 Antibody a Potential Characteristic Autoantibody for Sjögren's Syndrome?
Abstract BACKGROUND: Sjögren's syndrome (SS) is a common chronic inflammatory autoimmune disease, affects about 0.33% to 0.77% population in China. The positive for antinuc...
HMGB1 as a cytokine and therapeutic target
HMGB1 as a cytokine and therapeutic target
HMGB1 is an abundant nuclear and cytoplasmic protein present in mammalian cells. It is traditionally known as a DNA binding protein involved in maintenance of nucleosome structure ...
Neutrophil Extracellular Traps Facilitate Sympathoexcitation After Traumatic Brain Injury Via HMGB1/AP1 Signaling Pathway
Neutrophil Extracellular Traps Facilitate Sympathoexcitation After Traumatic Brain Injury Via HMGB1/AP1 Signaling Pathway
Abstract Background: Traumatic brain injury (TBI) usually accompanies with sympathetic excitation, and paradoxical sympathetic hyperactivity (PSH) may be detrimental to the...
Obésité : inflammation du tissu adipeux HMGB1, une nouvelle adipokine ?
Obésité : inflammation du tissu adipeux HMGB1, une nouvelle adipokine ?
L’obésité est aujourd’hui considérée comme une pandémie majeure et 2,8 millions d’adultes meurent chaque année de maladies associées à cette pathologie. Plus que l’augmentation de ...

Back to Top